AN2 Therapeutics (ANTX) Cash & Equivalents (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Cash & Equivalents data on file, last reported at $53.5 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $53.5 million, up 167.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $53.5 million (up 167.5% YoY), and the FY2025 annual result was $19.9 million, down 6.8% from the prior year.
• Cash & Equivalents climbed to $53.5 million in Q1 2026 per ANTX's latest filing, from $19.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $82.5 million in Q1 2022 and troughed at $15.6 million in Q4 2023.
• A 5-year average of $31.2 million and a median of $26.8 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents tumbled 67.63% in 2023, then soared 167.5% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $27.2 million in 2022, then sank by 42.69% to $15.6 million in 2023, then surged by 36.87% to $21.4 million in 2024, then decreased by 6.8% to $19.9 million in 2025, then soared by 168.84% to $53.5 million in 2026.
• Business Quant data shows ANTX's Cash & Equivalents at $53.5 million in Q1 2026, $19.9 million in Q4 2025, and $18.0 million in Q3 2025.